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Schizophrenia is a devastating disease that arises on the back-
ground of genetic predisposition and environmental risk factors,
such as early life stress (ELS). In this study, we show that ELS-
induced schizophrenia-like phenotypes in mice correlate with a
widespread increase of histone-deacetylase 1 (Hdac1) expression
that is linked to altered DNA methylation. Hdac1 overexpression
in neurons of the medial prefrontal cortex, but not in the dorsal
or ventral hippocampus, mimics schizophrenia-like phenotypes
induced by ELS. Systemic administration of an HDAC inhibitor res-
cues the detrimental effects of ELS when applied after the mani-
festation of disease phenotypes. In addition to the hippocampus
and prefrontal cortex, mice subjected to ELS exhibit increased
Hdac1 expression in blood. Moreover, Hdac1 levels are increased
in blood samples from patients with schizophrenia who had en-
countered ELS, compared with patients without ELS experience.
Our data suggest that HDAC1 inhibition should be considered as a
therapeutic approach to treat schizophrenia.
schizophrenia | histone-deacetylases | early life stress |
personalized medicine | HDAC inhibitor
Schizophrenia is a complex neuropsychological disorder thataffects ∼1% of the world’s population (1). It is characterized
by positive symptoms, such as delusions and hallucinations, and
by negative phenotypes, including impaired cognitive function
and social abilities (2, 3). A number of genes have been associ-
ated with the risk to develop schizophrenia (4–6). In addition to
genetic predisposition, environmental factors, such as urbanicity
(7), obstetric complications (8), or exposure to early life stress
(ELS) (9, 10), are known to increase the risk of develop-
ing schizophrenia. Such genome–environment interactions are
mediated by epigenetic processes, including DNA methylation
(DNAme) or histone modifications (11). Especially the role of
histone acetylation has gained substantial interest in trans-
lational neuroscience, which is due to the fact that inhibitors of
histone deacetylases (HDACs) enhance cognitive function and
ameliorate pathogenesis in a number of neurodegenerative and
neuropsychiatric diseases (12, 13). The human genome encodes
11 zinc-dependent HDACs that are grouped into three classes. The
emerging picture suggests that mainly class I HDACs might be
suitable targets to treat brain diseases (12, 14). HDAC inhibitors
are also discussed as novel targets to treat schizophrenia (15–17).
In fact, valproate given in combination with atypical antipsy-
chotics shows beneficial effects in preclinical (18) and clinical
(19) studies. These data have to be interpreted with care, how-
ever, because besides its action on HDACs, valproate affects
many other cellular processes (20). Postmortem analysis of hu-
man brain tissue suggested that Hdac1 levels are elevated in the
prefrontal cortex and hippocampus of patients with schizophrenia
(21, 22). It was therefore surprising that mutant mice either lacking
Significance
Early life stress (ELS) is an important risk factor for schizo-
phrenia. Our study shows that ELS in mice increases the levels
of histone-deacetylase (HDAC) 1 in brain and blood. Although
altered Hdac1 expression in response to ELS is widespread,
increased Hdac1 levels in the prefrontal cortex are responsible
for the development of schizophrenia-like phenotypes. In turn,
administration of an HDAC inhibitor ameliorates ELS-induced
schizophrenia-like phenotypes. We also show that Hdac1 levels
are increased in the brains of patients with schizophrenia and
in blood from patients who suffered from ELS, suggesting that
the analysis of Hdac1 expression in blood could be used for
patient stratification and individualized therapy.
Author contributions: S.B.-J., A.D., F.S., and A.F. designed research; S.B.-J., H.V., R.H., E.B.,
L.K., S.B., H.A.-S., I.A., M.B., R.M.S., D.E.D., C.F., H.F., K.G., U.H., M.K., C.K., S.Y.N., H.S., C.S.,
S. Stierl, J.S., A.T., M.v.H., J.Z., A.Z., S. Schulz, A.S., I.D., P.F., T.G.S., A.D., and F.S. performed
research; J.C. and J.M. contributed new reagents/analytic tools; S.B.-J., H.V., R.H., E.B., L.K.,
A.D., F.S., and A.F. analyzed data; H.A.-S., I.A., M.B., D.E.D., C.F., H.F., K.G., U.H., M.K., C.K.,
S.Y.N., H.S., C.S., S. Stierl, J.S., A.T., M.v.H., J.Z., A.Z., S. Schulz, P.F., and T.G.S. recruited and
phenotyped patients; and H.V., R.H., E.B., P.F., T.G.S., A.D., F.S., and A.F. wrote the paper.
The authors declare no conflict of interest.
This article is a PNAS Direct Submission.
Freely available online through the PNAS open access option.
Data deposition: Data from sequencing experiments reported in this paper have been
deposited in the Gene Expression Omnibus (GEO) database, https://www.ncbi.nlm.nih.
gov/geo (accession no. GSE90150).
1A.D., F.S., and A.F. contributed equally to this work.
2To whom correspondence should be addressed. Email: andre.fischer@dzne.de.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1613842114/-/DCSupplemental.
E4686–E4694 | PNAS | Published online May 22, 2017 www.pnas.org/cgi/doi/10.1073/pnas.1613842114
or overexpressing neuronal Hdac1 from early developmental stages
exhibit no cognitive phenotype (23). The lack of a phenotype
might be due to compensatory mechanisms during development,
because manipulating HDAC1 in the adult brain has been shown to
affect specific forms of cognitive function (14, 24).
In this study, we investigated the role of HDAC1 in the
pathogenesis of schizophrenia. We confirm that Hdac1 levels are
increased in the prefrontal cortex and hippocampus from pa-
tients with schizophrenia and show that increased Hdac1 ex-
pression in mice and humans is caused by ELS. Moreover, ELS
induces schizophrenia-like phenotypes in mice. These pheno-
types were rescued by systemic administration of the HDAC
inhibitor MS-275 (Entinostat). In turn, overexpression of Hdac1
in the medial prefrontal cortex (mPFC) led to impaired synaptic
plasticity, short-term memory, and prepulse inhibition of the
startle response (PPI). AlthoughHdac1 levels were also increased
in the hippocampus of patients with schizophrenia, manipulating
hippocampal HDAC1 levels had no effect on schizophrenia-like
phenotypes, suggesting that adverse early life events cause a
general increase in Hdac1 expression. Indeed, we observed in-
creased Hdac1 levels in blood samples from ELS mice and in
patients with schizophrenia who had experienced ELS. Our data
show that HDAC inhibition could represent a suitable thera-
peutic approach to treat schizophrenia and, moreover, suggest
that measuring Hdac1 levels in blood samples may allow patient
stratification and individualized therapy.
Results
We started our analysis by measuring Hdac1 levels in post-
mortem tissue from control individuals and patients with
schizophrenia. Our data reveal that Hdac1 mRNA (Fig. S1A)
and protein level (Fig. S1B) were elevated in the prefrontal
cortex (Brodmann area 9) of patients with schizophrenia. The
expression of other class I HDACs was not affected (Fig. S1A).
These data confirm previous results showing that Hdac1 is up-
regulated in postmortem brain samples from patients with
schizophrenia (21, 22) and provide further evidence that HDAC1
might play a role in the pathogenesis of neuropsychiatric diseases.
Because deletion or overexpression of Hdac1 in all neurons of the
mouse brain from prenatal stages did not cause any behavioral
changes (23), we speculated that elevated HDAC1 levels in pa-
tients with schizophrenia may be due to environmental risk fac-
tors that drive Hdac1 expression in the postnatal brain, thereby
limiting the effect of compensatory processes. One environmental
risk factor that has repeatedly, although not exclusively, been
linked to the pathogenesis of schizophrenia is ELS (25, 26), which
can be modeled in rodents (27). Thus, we hypothesized that ELS
might increase Hdac1 expression. To induce ELS, we subjected
mice to an adapted maternal separation paradigm (hereafter
simply referred to as ELS) (28) and performed behavior testing
when animals were 4 mo old [postnatal day 120 (PND120)]. Mice
that did not undergo the ELS protocol were used as a control
group. Explorative behavior assayed in the open field test did not
differ significantly (Fig. 1A). Basal anxiety, as measured in the
elevated plus maze test, was also similar across groups (Fig. S2).
Next, we measured short-term memory via the novel object rec-
ognition paradigm and observed that mice subjected to ELS
performed significantly worse compared with the control group
(Fig. 1B). Long-term memory was not affected (Fig. S2). We also
tested PPI, which is impaired in patients with schizophrenia and is
considered to be a reliable measure of schizophrenia-like phe-
notypes in rodents (29). PPI was significantly impaired in the ELS
group, whereas the basic startle response was similar across
groups (Fig. 1C). In conclusion, these data show that the ELS
protocol we used leads to schizophrenia-like phenotypes in mice.
Next, we measuredHdac1mRNA and protein levels in the mPFC
of 4-mo-old mice that were exposed to ELS. Compared with
the control group, we found that Hdac1 levels were significantly
increased, whereas other class I HDACs were not affected (Fig. 1
D and E). We hypothesized that ELS-induced changes of
HDAC1 levels may result from a failure to control Hdac1 ex-
pression during postnatal brain development. In line with this
idea, we observed that Hdac1 levels decrease in the postnatal
brain and that Hdac1 expression is similar between control and
ELS mice at PND34 (Fig. S3 A and B), a time point when ex-
plorative behavior, short-term memory, and PPI are still normal
in mice exposed to ELS (Fig. S3 D–F). To explore the mecha-
nisms contributing to ELS-induced increased Hdac1 expression,
we focused on DNAme. ELS has been associated with DNAme
changes that alter the ability of transcription factors, such as
glucocorticoid receptors (GRs), to bind DNA (30). The Hdac1
gene contains a GR binding site within the first exon that could
potentially be subjected to DNAme. We first performed meth-
ylated DNA immunoprecipitation (MeDIP), followed by next-
generation sequencing (NGS), from the mPFC of wild-type
mice (n = 5) to define methylated DNA regions (data available
via the Gene Expression Omnibus database, accession no.
GSE90150) and observed that the GR-binding site within the first
exon of Hdac1 is methylated (Fig. S4). Next, we used MeDIP,
followed by quantitative PCR (qPCR), to quantify DNAme at the
GR-binding site of the Hdac1 gene in the mPFC from control
mice and mice that were subjected to ELS (tissue was collected at
PND120). We found a highly significant decrease of DNAme in
the ELS group (Fig. 1F). Although no changes in DNAme were
detected at a non–GR-binding region of the Hdac1 gene (Fig. 1F
and Fig. S4), these data do not exclude the possibility that ELS
causes DNAme changes at other genomic loci, including addi-
tional GR-binding sites.
To test the role of HDAC1 more directly, we decided to use a
pharmacological approach. Therefore, mice were subjected to
our ELS paradigm (Fig. 2A). In agreement with our previous
Fig. 1. Expression of HDAC1 is elevated in mice exposed to ELS. (A) Mice
subjected to ELS show normal explorative behavior (n = 15 per group), al-
though there was a trend for locomotor hyperactivity (P = 0.069, unpaired
Student’s t test). (B) Short-term memory analyzed via the novel object rec-
ognition paradigm revealed impairment in ELS-exposed mice (*P < 0.05,
unpaired Student’s t test). (C) PPI was impaired in ELS mice. Two-way
ANOVA of repeated measurements showed a significant effect of ELS
[F(4,41) = 5.341, *P = 0.0259] and a significant effect of prepulse intensity
[F(4,164) = 2.123]. A Bonferroni post hoc test revealed significant impaired PPI
at 75 dB (P = 0.0089), 80 dB (P = 0.0356), and 85 dB (P = 0.0389). (D) Mice
were subjected to ELS, and the prefrontal cortex (PFC) was isolated at
PND120. qPCR analysis showed that Hdac1 mRNA is up-regulated in ELS-
exposed mice compared with the control group (n = 6 per group; **P <
0.01, unpaired Student’s t test). Other class I HDACs were not affected. A.U.,
arbitrary units; Rel., relative. (E) Immunoblot analysis (n = 5 per group)
confirmed elevated HDAC1 protein levels in the PFC from ELS-exposed mice.
Tissue was isolated at PND120 (*P < 0.05, unpaired Student’s t test). (F, Left)
MeDIP followed by qPCR shows that ELS leads to reduced DNAme of the
Hdac1 gene at the GR-binding site (**P < 0.01, unpaired Student’s t test; n =
5 per group). Tissue was isolated at PND120. (F, Right) MeDIP followed by
qPCR revealed no difference when a non-GR DNAme site within the Hdac1
gene was tested. Error bars indicate SEM.














data, mice subjected to ELS displayed impaired PPI when tested
at PND120 (Fig. 2B). Subsequently, mice of the ELS group were
randomly assigned into one group that received daily i.p. injec-
tions of the class I HDAC inhibitor MS-275 for 10 d (ELS–MS-
275 group). The other group of mice received vehicle injections
(ELS-vehicle group). At PND140, mice of both groups were
again subjected to PPI testing. PPI was significantly increased
in MS-275–treated mice (Fig. 2C), although the basic startle
response (Fig. 2D) and explorative behavior (Fig. S5) were not
affected. An additional group of animals was subjected to the
same experimental approach and tested for short-term memory
in the novel object recognition paradigm. We first confirmed
impaired short-term memory in the ELS group tested at PND120
(Fig. 2E). Treatment with MS-275 ameliorated this phenotype
when animals were trained again in the novel object recognition
test at PND140 (Fig. 2E). Because MS-275 is not a specific in-
hibitor of HDAC1, we sought to provide genetic evidence that
HDAC1 can cause schizophrenia-like phenotypes in mice. There-
fore, we used a viral-mediated approach to overexpress HDAC1
[HDAC1-adeno-associated virus (AAV)] under the control of
the synapsin promoter, thereby restricting expression to neuronal
cells (14). Although endogenous HDAC1 is moderately
expressed in neurons of the prefrontal cortex (23) (Fig. S6), in-
jection of HDAC1-AAV particles into the mPFC of mice caused
a two- to threefold overexpression of HDAC1 protein (Fig. 3A
and Fig. S6), which closely mimicked the situation seen in human
patients with schizophrenia and in mice subjected to ELS (Fig. 1
and Fig. S1). Thus, we injected HDAC1-AAV particles into the
prefrontal cortex of mice at 2 mo of age. Mice injected with GFP-
AAV particles served as controls. Immunohistochemical analysis
suggested that 82.6% of the neurons within the transfected region
of the mPFC exhibited increased HDAC1 expression (Fig. S6). At
3 mo of age, animals were subjected to behavioral testing. Al-
though explorative behavior assayed in the open field test was
similar across groups (Fig. 3B), we found that short-term memory
in the novel object recognition task was significantly impaired in
the HDAC1-AAV group compared with the GFP-AAV control
group (Fig. 3C). Most importantly, sensory-motor gating function
measured via PPI was also impaired in the HDAC1-AAV group
(Fig. 3D). In conclusion, these data provide strong evidence that
elevated levels of HDAC1 in neurons of the mPFC contribute to
schizophrenia-like phenotypes. To gain further mechanistic insight,
we decided to assess whether overexpression of HDAC1 would
affect synaptic transmission and plasticity. As described before,
2-mo-old mice were injected with either HDAC1-AAV or GFP-
AAV into the mPFC and were subjected to analysis at 3 mo of
age to allow direct comparison with the results obtained by be-
havioral analysis. We first recorded evoked-field excitatory post-
synaptic potentials (fEPSPs) in layer II through layer V pyramidal
cell synapses in acute mPFC slices from AAV-GFP– or AAV-
HDAC1-GFP–injected mice. To investigate the effects of
HDAC1 expression on basal excitatory synaptic transmission,
stimulus–response curves were calculated for slope of fEPSPs
in layer V of the mPFC. Two-way ANOVA with repeated
measures detected statistically significant differences in the
stimulus–response curves between AAV-GFP and AAV-
HDAC1-GFP mice (Fig. 3E). Accordingly, the basal (50%)
fEPSP amplitude in AAV-HDAC1-GFP slices (343 ± 22 μV)
was significantly smaller compared with AAV-GFP controls
(455 ± 25 μV; Fig. 3F). The paired-pulse ratio at a 50-ms inter-
pulse interval, a measure of short-term plasticity, was not signifi-
cantly different between the two groups (Fig. 3G), suggesting that
the deficit in synaptic transmission is due to postsynaptic defects
rather than presynaptic defects.
Analysis of synaptic plasticity elicited by repetitive theta-burst
stimulation (TBS) revealed that the levels of long-term potentia-
tion (LTP) recorded in the mPFC of AAV-HDAC1-GFP mice
(108.23 ± 4.05%) were significantly lower compared with AAV-
GFP mice (134.65 ± 5.23%; Fig. 3H). Also, for short-term po-
tentiation (STP), there was a strong tendency for reduction in
AAV-HDAC1-GFP–injected mice (182.43 ± 11.42%) versus
AAV-GFP–injected mice (229.31 ± 18.50%; Fig. 3H). Notably,
neither AAV-HDAC1-GFP nor AAV-GFP slices displayed a sig-
nificant correlation between LTP and basal fEPSP slope, or be-
tween LTP and STP, as determined by analysis of Pearson’s and
Spearman’s coefficients of correlation (Fig. S7). Thus, our data
indicate that overexpression of neuronal HDAC1 leads to multiple
independent deficits in synaptic transmission and plasticity.
Next, we aimed to explore the impact of HDAC1 on gene
expression using ChIP analysis. To this end, we first selected
genes that had been linked to schizophrenia (Fig. S8). We found
that the expression of Gad1, a gene encoding glutamate decar-
boxylase 1, Pvalb, which encodes parvalbumin, and the Kcnv1
gene, which encodes potassium channel subfamily V member 1,
were decreased in the prefrontal cortex from patients with
schizophrenia (Fig. 4A). A similar reduction of expression was
observed in the mPFC of mice subjected to ELS and in animals
that overexpressed HDAC1 (Fig. 4 B and C). Therefore, we were
able to perform ChIP analysis to measure the levels of HDAC1
bound to the Gad1, Pvalb, and Kcnv1 promoters in human pa-
tients with schizophrenia, in mice subjected to ELS, and in mice
overexpressing HDAC1. Consistent with the down-regulation
of the Gad1, Pvalb, and Kcnv1 genes, we observed significantly
increased HDAC1 binding at the promoter regions of these
genes in human patients with schizophrenia (Fig. 4D) and in the
corresponding animal models (Fig. 4 E and F). In agreement
with this observation, H3K9 acetylation was reduced within the
Gad1, Pvalb, and Kcnv1 gene promoters (Fig. S9). Moreover,
reduced H3K9ac and gene expression after ELS exposure was
Fig. 2. HDAC inhibitor MS-274 rescues ELS-induced impairment in PPI.
(A) Experimental design. (B) Mice (n = 33) were subjected to ELS (ELS–PPI-1 group).
PPI was significantly impaired at PND120 compared with a control group
(n = 34). Two-way ANOVA of repeated measurements (RM) showed a
significant effect of ELS [F(1,66) = 5.213, P = 0.025]. A Bonferroni post hoc
test revealed significantly impaired PPI (*P < 0.05) at 75–85 dB. (C) Ten days
after behavioral characterization, ELS–PPI-1 mice were assigned to two
groups. One group of ELS mice (n = 8) was injected i.p. daily for 10 d with
MS-275 (12.5 mg/kg, ELS–MS275–PPI-2 group), whereas the other group of
ELS mice received vehicle injections (ELS-vehicle–PPI-2 group, n = 14).
Twenty-four hours after the last injection, mice were subjected to a second
PPI test (PPI-2). MS-275 treatment improved PPI performance compared with
the vehicle group. Two-way ANOVA of RM showed a significant effect of
MS-275 treatment [F(1,21) = 4.917, P = 0.0378], and the Bonferroni post hoc
test revealed significantly improved PPI responses at 70–80 dB (*P < 0.05) in
MS-275–treated mice. (D) Startle response was not affected. (E, Left) At
PND120, novel object recognition learning is impaired in mice subjected to
ELS (n = 18) compared with a control group (n = 11; ***P < 0.001, unpaired
Student’s t test). (E, Right) Mice subjected to ELS but treated with MS-
275 from PND130–140 (n = 9) show improved novel object recognition
memory compared with a vehicle control group (n = 9; ***P < 0.001; un-
paired Student’s t test). Error bars indicate SEM.
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ameliorated in mice treated with MS-275 (Fig. S9). These data
do not exclude the possibility that other mechanisms, such as
DNAme, contribute to the down-regulation of these genes after
ELS exposure. Indeed, we observed that DNAme at the Pvalb
promoter was increased after ELS (Fig. S10). The same trend
was also observed in mice overexpressing HDAC1, however,
which is in line with previous findings showing that HDAC1 can
form complexes with DNA methyltransferases (31, 32). At least
in the case of Pvalb, these data suggest that increased HDAC1
function acts in concert with DNAme changes to regulate Pvalb
expression. DNAme most likely also contributes to ELS-induced
changes in gene expression that are independent of HDAC1
action, an issue that needs to be addressed in future research.
To test if the observed phenotypes are specific to the mPFC,
we also analyzed HDAC1 levels in the hippocampus of patients
with schizophrenia. Similar to the data observed in the cortex,
Hdac1 mRNA and protein levels were elevated in patients with
schizophrenia (Fig. S11 A and B). Similarly, exposing mice to
ELS caused elevated hippocampal Hdac1 levels (Fig. S11C). We
had previously shown that overexpression of HDAC1 in the
dorsal hippocampus of mice did not affect PPI or short-term
memory (14). The possibility remained, however, that increased
expression of HDAC1 in the ventral hippocampus, which is linked
to regulation of mood and anxiety, and moreover directly projects
to the mPFC (33, 34), may contribute to schizophrenia-like phe-
notypes in mice. To test this possibility, we injected AAV-HDAC1-
GFP or AAV-GFP particles into the ventral hippocampus of mice
and performed behavioral testing 4 wk later. Immunohistochemi-
cal analysis suggested that 95% of the hippocampal neurons within
the infected area express HDAC1-GFP (Fig. S11D). Of note, in-
creased levels of HDAC1 in the ventral hippocampus did not af-
fect explorative behavior, short-term memory, or PPI (Fig. S11 E–
G). These data suggest that increased expression of HDAC1 in
patients with schizophrenia might be a common phenomenon that
is not restricted to one brain region. Nevertheless, the detrimental
phenotypes seem to be specifically linked to the action of
HDAC1 in the prefrontal cortex and do not involve hippocampal
function.
If this hypothesis is true, HDAC1 might be a suitable bio-
marker for patient stratification and individualized therapy.
Thus, we speculated that increased Hdac1 levels might also be
observed in the blood of mice subjected to ELS. Indeed, qPCR
analysis revealed increased Hdac1 levels in blood samples
(obtained at PND120) of mice subjected to ELS (Fig. 5A). Next,
we set out experiments to test if our findings can be translated to
human patients. To this end, we relied on an ongoing study on
genotype–phenotype relationships and the neurobiology of the
longitudinal course of major psychiatric disorders (www.kfo241.de
and www.psycourse.de). From this cohort, we selected patients
suffering from paranoid schizophrenia [Diagnostic and Statistical
Manual, 4th Edition (DSM-IV) diagnosis code 295.30 (35)] who
Fig. 3. Increasing HDAC1 levels in the mPFC causes schizophrenia-like
phenotypes. (A) AVV-HDAC1-GFP particles were injected into the PFC. Ro-
bust nuclear HDAC1-GFP expression in neurons was detected 14 d after in-
jection. The image shows low-magnification (Left) and high-magnification
(Right) images illustrating HDAC1-GFP immunoreactivity. CC, corpus cal-
losum. (Scale bars: Left, 50 μm; Right, 10 μm.) Costaining with parvalbumin
(red) shows expression of HDAC1-GFP in inhibitory neurons. Because HDAC1-
GFP is expressed via the synapsin promoter, its expression is restricted to
neurons. *P < 0.05. (B) Explorative behavior was similar when comparing
mice injected with AAV-HDAC1-GFP (n = 6) versus AAV-GFP (n = 6).
(C) Short-term memory measured in the novel object recognition test was
impaired in AAV-HDAC1-GFP-mice (n = 8) compared with the control group
(n = 8; **P = 0.0031, unpaired Student’s t test). (D) PPI was impaired in AAV-
HDAC1-GFP mice. Two-way ANOVA of repeated measures showed a signif-
icant effect of virus expression [F(4,27) = 5.640, P = 0.0249] and a significant
effect of prepulse intensity [F(4,108) = 2.123, P = 0.0829]. A Bonferroni post
hoc test revealed significantly impaired PPI in HDAC1-GFP mice at 75 dB
(*P = 0.0432507), 80 dB (*P = 0.010581), 85 dB (*P = 0.0242066), and 90 dB
(*P = 0.0242066). (E) Relationships between stimulus intensity and slope of
evoked fEPSPs. A two-way ANOVA with repeated measures revealed sig-
nificant effects of HDAC1 [F(1,126) = 7.261, P = 0.017], stimulus intensity
[F(9,126) = 126.225, P < 0.001] and interaction between HDAC1 and stimulus
intensity [F(9,126) = 5.203, P < 0.001]. A Holm–Sidak post hoc test revealed
significantly reduced fEPSP slope in AAV-HDAC1-GFP–injected mice at 55 μA
(*P = 0.026), 60 μA (**P = 0.003), 65 μA (**P = 0.001), 70 μA (**P = 0.002), 75 μA
(**P = 0.003), 80 μA (**P = 0.008), and 85 μA (*P = 0.018). (Left Inset)
Representative examples, which are averages of three to five fEPSPs evoked
at 45 μA (green), 50 μA (red), and 55 μA (blue) in AAV-GFP– and AAV-
HDAC1-GFP–injected mice. (Right Inset) Note that AAV-HDAC1-GFP–
expressing slices displayed a detectable population spike already at 50 μA (red
thick trace). (F) AAV-HDAC1-GFP–expressing brain slices showed reduced basal
excitatory transmission (**P = 0.004, unpaired Student’s t test). (G) Un-
altered PPF (P = 0.149, unpaired Student’s t test), measured as the ratio
between the slopes of second and first fEPSPs (%) at a 50-ms interstimulus
interval in AAV-HDAC1-GFP–injected mice. (Inset) Representative examples
of PPF of fEPSPs in AAV-GFP–expressing (dark green) and AAV-HDAC1-GFP–
expressing (light green) slices. (H, Left) HDAC1-GFP–expressing mice showed
impaired LTP (50–60 min after TBS; **P = 0.001, unpaired Student’s t test)
and a tendency for a decrease in STP (#P = 0.05, unpaired Student’s t test).
The mean slope of fEPSPs recorded during a baseline period of 10 min be-
fore TBS was taken was 100%, and an arrow indicates delivery of TBS. (H,
Right) Representative examples of fEPSPs, which are averages of 30 fEPSPs
recorded during 10 min before (black, baseline) or 50–60 min after (gray)
induction of LTP, respectively. Data represent measures from eight to nine
slices recorded from five AAV-GFP–expressing mice and seven to eight slices
from four AAV-HDAC1-GFP–expressing mice. The experiments described in
B–H were performed 4 wk after injection. Error bars indicate SEM.














were diagnosed using a comprehensive phenotyping inventory
(details are provided in Materials/Subjects and Methods) also
assessing ELS (36, 37). Thus, we were able to classify patients
with schizophrenia as either having experienced ELS (n = 38) or
not (n = 39).
There was no significant age difference among male patients,
although female patients with ELS were slightly older than fe-
male patients without ELS (Fig. S12). Next, we isolated RNA
from all samples and performed qPCR analysis for Hdac1.
Hdac1 mRNA was significantly increased in female (n = 14) and
male (n = 24) patients with schizophrenia who encountered ELS
compared with patients who were not exposed to ELS (nfemale =
13, nmale = 26) (Fig. 5 B and C).
Discussion
In this study, we show that Hdac1 mRNA and protein levels are
increased in postmortem brain tissue, namely, in the hippo-
campus and prefrontal cortex of patients with schizophrenia. Our
findings confirm previous studies that reported elevated Hdac1
expression in patients with schizophrenia (21, 22). Together with
our observation that overexpression of HDAC1 in neurons of the
mPFC of mice leads to schizophrenia-like phenotypes, these data
provide solid evidence for a role of HDAC in the pathogenesis of
schizophrenia. It has to be noted that no animal model reca-
pitulates all of the complex phenotypes observed in human pa-
tients. For example, we did not observe locomotor hyperactivity,
which is know to occur in human patients and some animal
models (38). Our data suggest that the up-regulation of HDAC1
in patients with schizophrenia is due to environmental risk fac-
tors, especially ELS. It is noteworthy that ELS-induced HDAC1
expression may result from the deregulation of processes that
control Hdac1 expression during normal brain development.
This assumption is based on the finding that cortical HDAC1
expression normally decreases from PND0 to PND120, whereas
ELS exposure appears to disturb this process. This observation is
in agreement with previous studies indicating that exposure to
environmental risk factors can cause long-lasting changes in
DNAme and gene expression (39, 40). It will be interesting to
determine what aspect of the stress system induces ELS-
mediated HDAC1 expression. Causative evidence that increased
HDAC1 levels contribute to the pathogenesis of schizophrenia
stems from our observation that the HDAC inhibitor MS-
275 ameliorates ELS-induced phenotypes and that overexpression
of HDAC1 in the prefrontal cortex leads to impaired short-term
memory, synaptic plasticity, and PPI. It would be interesting to test
if Hdac1 knockout mice are resistant to ELS-induced phenotypes.
Moreover, we cannot distinguish if the phenotypes caused by in-
creased HDAC1 expression are exclusively due to its catalytic
activity or may also involve processes independent of HDAC1
activity. The view that HDAC1-mediated gene expression plays a
role in the development of schizophrenia-like phenotypes is sup-
ported by our finding that HDAC levels were increased at the
promoter regions of three genes implicated in schizophrenia,
namely, Pvalb, Gad1, and Kcnv1. Increased promoter binding of
HDAC1 was associated with reduced expression of these genes,
which was observed in patients, in mice exposed to ELS, and in
mice overexpressing HDAC1. Because HDAC1 levels were spe-
cifically increased in neurons in our overexpression model, we
suggest that increased expression of neuronal HDAC1 is sufficient
to drive schizophrenia-like phenotypes in mice. This finding is in
line with the reported predominantly neuronal expression pattern
of HDAC1 in the adult brain (14, 23). However, in our experi-
mental approach, we cannot distinguish between different neu-
ronal populations. In the future, it will be important to determine
the precise cell types in which HDAC1 is increased in response to
ELS and to decipher how HDAC1 impacts the plasticity of the
corresponding neuronal circuits. The finding that HDAC1 affects
the expression of Gad1 and Pvalb indicates a role in inhibitory
neurons, which is in line with a previous study showing that HDAC1
is expressed in GABAergic neurons regulating GAD1 expression
(41). Gad1, Pvalb, and Kcnv1 were selected for analysis as exam-
ples (Fig. S8). There are certainly additional genes deregulated in
response to increased HDAC1 levels, and future genome-wide
approaches will be necessary to identify these networks. We ob-
served reduced basal excitatory synaptic transmission and im-
paired N-methyl-D-aspartate receptor-dependent LTP in the
prefrontal cortex of mice overexpressing neuronal HDAC1. We
also observed a deficit in basal synaptic transmission, which is in
line with an observation that HDAC1 acts as a transcriptional
repressor of GluR2 subunit-containing α-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid receptors, thereby down-regulating
synaptic strength (42). It is therefore likely that increased HDAC1
affects the function of multiple neuronal cell types and cellular
Fig. 4. Elevated HDAC1 levels affect the expression of genes linked to
schizophrenia. (A) qPCR analysis reveals elevated expression of the genes
encoding Pvalb, Gad1, and Kcnv1 in the prefrontal cortex of patients with
schizophrenia (n = 9 per group; *P < 0.05, unpaired Student’s t test) and in
the mPFC of mice subjected to ELS compared with the control group (n =
5 per group; *P < 0.05, unpaired Student’s t test). Similar data were obtained
in mice subjected to ELS (B; n = 5 per group; *P < 0.05, unpaired Student’s
t test) and in mice that received AAV-HDAC1-GFP injections compared with
the HDAC-GFP control group (C; n = 5 per group; *P < 0.05, unpaired Stu-
dent’s t test). (D) ChIP analysis reveals increased HDAC1 levels at the gene
promoters of Pvalb, GAD1, and Kcnv1 in the prefrontal cortex of patients
with schizophrenia and compared with controls (n = 8 per group; *P < 0.05,
unpaired Student’s t test). Similar data were obtained in the mPFC of mice
subjected to ELS (n = 5) compared with the corresponding control group (E;
n = 5 per group; *P < 0.05, unpaired t test) and in mice that received AAV-
HDAC1-GFP injections compared with the HDAC1-GFP group (F; n = 5 per
group; *P < 0.05, unpaired Student’s t test). Tissue from the ELS group and
corresponding control group was isolated at PND120. Tissue from AAV-
injected mice was harvested 4 wk after injection. Error bars indicate SEM.
Fig. 5. Hdac1 levels are increased in blood samples from patients with
schizophrenia who were subjected to ELS. (A) qPCR analysis showing in-
creased Hdac1 expression in blood isolated from ELS-exposed mice at
PND120.Hdac1 levels were significantly increased in the ELS group (n = 15 per
group; *P < 0.05, unpaired Student’s t test) (B) Increased Hdac1 expression in
female patients with schizophrenia (n = 14) exposed to ELS compared with
the no-ELS group (n = 13; *P = 0.0129, unpaired t test). (C) Increased Hdac1
expression in male patients with schizophrenia exposed to ELS (n = 24)
compared with the no-ELS group (n = 24; **P = 0.001, unpaired t test). Error
bars indicate SEM.
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pathways. Another interesting observation is that HDAC1 levels
are elevated in the mPFC and hippocampus of patients with
schizophrenia and mice exposed to ELS. However, only over-
expression of HDAC1 in the mPFC, but not in the dorsal (14) or
ventral hippocampus (this study), causes schizophrenia-like phe-
notypes. This finding indicates that HDAC1 in the mPFC, a brain
region intimately linked to schizophrenia (43, 44), may control
different molecular pathways compared with other brain regions,
such as the hippocampus. In line with this observation, the con-
centration of systemically injected MS-275 leading to increased
bulk levels of histone 3 acetylation in the prefrontal cortex of mice
is fourfold lower compared with the dose needed to observe the
same effect in hippocampal tissue (45). Interestingly, we also ob-
served increased HDAC1 levels in blood samples from mice ex-
posed to ELS and in patients with schizophrenia. Although
increased HDAC1 levels in blood are unlikely to contribute to
schizophrenia-like phenotypes, this finding is in line with the view
that adverse early life events and other risk factors induce similar
gene expression changes in various cell types (46).
Taken together, these findings suggest that exposure to ELS
leads to increased HDAC1 expression in several tissues and cell
types. However, only in selected cells, such as neurons of the
mPFC, will increased HDAC1 expression trigger pathological
events. It will be interesting to understand the molecular basis
for this phenomenon.
It has to be mentioned that a previous study reported reduced
HDAC1 level in the prefrontal cortex of mice exposed to ELS,
which was also linked to cognitive deficits, however (47). The
discrepancy between that study and our data is likely due to the
fact that an infant maternal separation protocol and BALB/c
mice were used (47). It is well known that BALB/c and C57BL6J
mice differ regarding cognitive function and stimulus-induced
gene expression (48, 49). Moreover, there is by now substantial
evidence from independent studies (refs. 21, 22 and this study)
that HDAC1 levels are increased in human patients with
schizophrenia, that overexpression of HDAC1 in the prefrontal
cortex of mice increases stereotype behavior (24) and induces
schizophrenia-like phenotypes (this study), and that the HDAC
inhibitor MS-275 alleviates cognitive phenotypes (ref. 50 and
this study).
Nevertheless, great care has to be taken when interpreting
results from animal experiments in the context of human dis-
eases. This caution is especially true for complex diseases such as
schizophrenia. However, the relevance of our findings is sub-
stantiated by the observation that HDAC1 levels are increased in
blood samples from patients with schizophrenia who had en-
countered ELS, compared with patients without ELS.
In conclusion, our data strongly support a role of HDAC1
function in the etiology of schizophrenia. Elevated HDAC1 ex-
pression is likely due to adverse environmental factors, such as
ELS, that occur within a vulnerable postnatal phase. The finding
that altered DNAme may play a key role in the up-regulation of
HDAC1 also merits further investigation and suggests that com-
binational therapies or even dietary changes that are known to
affect DNAme (51) could be suitable therapeutic strategies. We
show that the analysis of HDAC1 levels in blood from patients
allows the identification of individuals with ELS experience.
Therefore, this biomarker approach might be useful to identify
schizophrenic patients who will benefit from therapeutic in-
tervention with HDAC inhibitors. In addition, it should be tested if
DNAme of the Hdac1 gene could also be used as a biomarker. It
will also be interesting to see if different stressors will affect blood
Hdac1 levels and if patients that experienced ELS can be further
classified based on the categories of stressors. Although some
drugs, such as MS-275/Entinostat, are in clinical testing, other
HDAC inhibitors, such as vorinostat or valproate, are already in
clinical use. The latter are even used for the treatment of psychosis.
Our data therefore point to two immediate translational avenues.
First, blood Hdac1 levels should be measured when treating
schizophrenic patients with valproate to correlate therapeutic ef-
ficacy with Hdac1 levels, and, second, more specific compounds,
such as the US Food and Drug Administration-approved HDAC
inhibitor vorinostat, should be tested in clinical studies treating
schizophrenic patients with ELS experience and/or elevated blood
Hdac1 levels. In sum, our data may help to develop better thera-
peutic avenues to treat schizophrenia.
Materials/Subjects and Methods
Animals and Behavioral Experiments. Mice (C57BL/6J) were housed under
standard conditions with free access to food and water. All experiments were
carried out in accordance with the animal protection law and were approved
by the District Government of Germany (Animal Care protocol 10/0186).
Maternal separation (ELS) was performed according to a recent protocol
published by Niwa et al. (28). In brief, the mothers were removed from the
cage and the pups were subsequently placed in a Petri dish filled with
bedding. The dish was then placed for 6 h each day in a different room
(32 °C) before the pups were returned to their mothers. Control groups were
handled identically, but not removed from their mothers. At day 22, mice
were weaned and then housed in isolation.
The open field test was performed to assay explorative behavior and
locomotion. Eachmouse was placed in the center of an open arena (length of
1 m, width of 1 m, side walls were 20 cm high), and behavioral activity was
recorded for 5 min using the VideoMot2 tracking system (TSE Systems).
The elevated plus maze test was used to test basal anxiety. Animals were
placed individually in a uniformly gray plastic arena consisting of two non-
walled (open) and two walled (closed) arms for 5 min (10 × 40 cm each, walls
were 40 cm high). Time spent in open versus closed arms was measured
using a camera (VideoMot2 system).
The novel object recognition test was used tomeasure short-termmemory in
mice. Mice were habituated to an open arena (length of 1 m, width of 1 m, side
walls were 20 cm high) for 5 min on two consecutive days. Twenty-four hours
after this habituation period, mice were exposed for 5 min to the familiar arena
with two identical objects placed at an equal distance (18 cm from the side
walls). During a short retention period in the home cage for 5 min, one of the
two identical objects was replaced with a new object. During the testing phase,
mice were exposed to this situation and short-term memory was assessed by
scoring exploration of the new object on the basis of direct contact with the
object using the VideoMot2 tracking system. For the assessment of long-term
memory, the test was performed as described above but mice were exposed
to the novel object not 5 min but 24 h after the initial exposure to the two
familiar objects. In case of the experiments described in Fig. 2E, the objects used
from training at PND120 and after vehicle or MS-275 treatment were different.
The index for object preference was calculated as the percentage of time spent
with the novel object using the following formula: (time spent with novel
object/time spent with both objects) * 100%.
PPIwasused tomeasure sensorimotor gating function. The experimentswere
conducted as previously described using an apparatus from TSA Systems. In
brief, mice were placed individually in a small cylindrical cage with an in-
tegrated stainless floor grid (80 × 40 × 45 cm) that was placed on a sensitive
transducer platform in a sound-attenuating cabinet. Acoustic stimuli were
delivered through loudspeakers above the cage and startle response signals
presented by TSA startle response software. During one test session, mice were
habituated first for 3 min to 65-dB background noise, followed by a 2-min
baseline recording. After the baseline recording, mice were exposed to six
pulse-alone trials, with each consisting of 120-dB startle stimuli intensity for a
duration of 40 ms to decrease the influence of within-session habituation and
to scale down the initial startle response to a stable plateau. The startle re-
action to acoustic stimuli was recorded with the presentation of the startle
stimuli for a time window of 100 ms. PPI of startle activity was conducted by
trials presenting startle stimuli at 120 dB for 40 ms alone or preceding non-
startling prepulses of 5, 10, 15, 20, and 25 dB above the 65-dB background
noise (i.e., 70, 75, 80, 85, 90 dB). An interval of 100 ms with background nose
was introduced between each prepulse and pulse-alone stimulus. Each trial
(startle pulse alone; pulse preceded by 70, 75, or 80 dB; or no stimulus) was
presented in a pseudorandom order, with intertrial intervals ranging from 8 to
22 s. The startle response amplitude was defined as the average of the maxi-
mum force detected during a reaction to a 120-dB startle stimulus. The per-
centage of PPI was calculated using the following formula: (%) = 100 − [(startle
amplitude after prepulse and pulse)/(startle amplitude after pulse only) * 100].
Patients with Schizophrenia. Postmortem tissue frompatientswith schizophrenia
and controls was obtained with ethical approval and upon informed consent














from the Harvard Brain Tissue Resource Center (Boston), Brainnet Europe II
(Munich), and the brain bank of Hospital Sant Joan de Deu (Spain). Samples
were matched for age and postmortem delay.
For analysis of blood samples, the patients were recruited from a large
network of clinical centers across Germany, comprising both academic and
nonacademic facilities. These centers are clinical collaborators of an ongo-
ing study on genotype–phenotype relationships and the neurobiology of
the longitudinal course of major psychiatric disorders (www.kfo241.de and
www.PsyCourse.de). This study combines comprehensive longitudinal deep
phenotyping, longitudinal sampling of various types of biomaterial, and
state-of-the art proband management and biobanking, as well as advanced
data protection, governed by stringent standard operating procedures for a
multicenter study framework like ours (52–55). Blood was collected in Pax
gene tubes and incubated for 2 h at room temperature. Subsequently, tubes
were stored at −20 °C for 72 h before being transferred to −80 °C for long-
term storage. RNA was then isolated according to a user’s manual. All pa-
tients included in this study were suffering from paranoid schizophrenia
[DSM-IV diagnosis code 295.30 (35)]. They were diagnosed using a compre-
hensive phenotyping inventory, including a structured diagnostic interview
(56), clinical rating scales, questionnaires, and additional information sys-
tematically gleaned from medical records (whenever available). Structured
diagnostic interviews and rating scales were administered by psychologists,
graduate students with at least a bachelor’s degree in psychology, board-
certified psychiatrists, or psychiatric residents who underwent training in
structured diagnostic assessments. For the assessment of ELS, we asked pa-
tients to complete the childhood trauma screener (CTS) (31). The CTS is a
five-item questionnaire measuring physical, sexual, and emotional abuse, as
well as physical and emotional neglect, in childhood and adolescence. Based
on validated threshold values (32), patients were classified as either having
experienced ELS (n = 38) or not (n = 39). For human samples, written in-
formed consent was obtained from all study participants before inclusion to
the study from the local ethical committees. The experiments were approved
by the ethical committee of the Georg-August University Göttingen, and the
ethical committee of the Ludwig-Maximilians University, Munich.
Injection of MS-725. For i.p. injections of MS-275, a protocol previously de-
scribed by Engmann et al. (50) was applied. In brief, MS-275 stock solution
(100 μg/μL) was diluted 1:80 in DMSO and PBS to obtain a 1.25-μg/μL working
solution. Mice were then injected i.p. with 12.5 mg/kg of MS-275 for 10 d.
Control mice received a PBS-DMSO mixture.
Stereotaxic Injection of AAV Particles. For stereotaxic injections of AAV par-
ticles in the prefrontal cortex and ventral hippocampus of mice, animals were
anesthetized and placed in a stereotaxic frame, and the heads of mice were
cleaned and disinfected with 70% ethanol. After removal of the skin and
connective tissue on the skull, two holes were drilled according to the desired
coordinates. In the case of the prefrontal cortex, the two holes were drilled
according to the following coordinates: anterior/posterior, +1.40 mm relative
to bregma; medial/lateral ±0.45 mm. In the case of the ventral hippocampus,
the coordinates were as follows: anterior/posterior, −3.00 mm relative to
bregma; medial/lateral ±3.00 mm. Glass capillaries filled with mineral oil on
the top, a small air bubble in the middle, and respective AAV particles in the
bottom were placed on a Nanoliter 2000 microinjector. The microinjector
was connected to an ultra-microsyringe pump to control the speed and
volume of injection. For injections with HDAC1-GFP-AAV or GFP-AAV, 1 μL
with 1.0 * 108 transducing units was injected per hemisphere.
Tissue Dissection and RNA Isolation. Mice were killed by cervical dislocation,
and the brain tissue was quickly isolated on ice. Unless otherwise indicated,
tissue was harvested immediately after the end of the experiment. Tissue was
snap-frozen in liquid nitrogen and stored at −80 °C until processing. For RNA
extraction, tissue was homogenized in TRI Reagent (Sigma–Aldrich) and RNA
was extracted according to the manufacturer’s instructions. RNA was treated
with DNaseI (Invitrogen) before sequencing. Briefly, RNA was resuspended
in water and treated with 2 units of DNaseI for 20 min at 37 °C. DNA-free
RNA was then repurified with phenol/chloroform and resuspended in diethyl
pyrocarbonate water according to standard protocols. RNA was stored at
−80 °C (57).
qPCR. Total RNA was extracted using the TRI Reagent according to the
manufacturer’s recommendations, and the concentration of RNA was de-
termined using a Nano-Drop ND-1000 spectrophotometer (Thermo Scientific)
and a bioanalyzer (Stratagene). RNA samples were reverse-transcribed into
first-strand cDNA with reverse transcriptase (Roche). Real-time PCR detection
of a desired sequence was carried out using an LC480 LightCycler (Roche
Applied Science). Primers for gene expression analysis were obtained
according to the Universal Probe Library (Roche). Data were normalized to
the housekeeping gene Gapdh. Primers used for ChIP and MeDIP were
custom-made (a list of primers is provided in Table S1).
MeDIP/ChIP.
MeDIP. Sample preparation for MeDIP and sequencing was conducted
as described previously (58). We isolated the mPFC from five mice at 3 mo
of age and performed MeDIP sequencing for all five samples. Briefly, 200 ng
of sheared genomic DNA was end-repaired and adaptor-ligated using a
NEBNext ChIP-Seq Library Prep Master Mix Set for Illumina (E6240 kit; New
England Biolabs), followed by the immunoprecipitation of methylated
regions using 5-mC monoclonal antibody (BI-MECY-0100; Eurogentech).
Immunoprecipitated as well as input DNA was PCR-amplified using 2×
Phusion High-Fidelity PCR Master Mix (ThermoFisher Scientific) as per the
kit’s protocol. Sequencing for MeDIP and input DNA libraries was performed
on a HiSeq 2000 instrument (Illumina) using the standard Illumina protocol
at Fasteris SA. Sequenced reads were mapped using Bowtie 2 (59), and
further analysis for methylated regions was done with the MEDIPS package
(60) using input as a control. A false discovery rate of 0.1 was taken as the
cutoff value for significantly methylated regions compared with input
samples. Methylated regions were annotated using the R package ChIP-
seeker. BAM files for all replicates were merged, sorted, and indexed using
SAMtools. A WIG file was produced via the MEDIPS package and was used
for visualization in the Integrative Genome Browser. The program ngsplot
was used to plot the DNAme across the high-, medium-, and low-expressed
genes. Genes ware classified into high-, medium-, and low-expressed
according to expression level as mentioned earlier (58). Briefly, we calcu-
lated the fragments per kilobase of exon per million reads (FPKM) values for
the genes of the RNA-sequencing data from the same region from wild-type
mice (n = 3) using cufflinks. Genes with an average FPKM between 1 and
5 were considered as low-expressed genes, genes with 5–30 FPKM were
considered as medium-expressed genes, and genes with an FPKM higher
than 30 were considered as high-expressed genes. An aggregate gene plot
was created using ngsplot with the parameters −MW 5 (smoothing of av-
erage profiles), −RB 0.01 (trimmed mean to remove extreme values), and −F
protein_coding. For ELS samples, immunoprecipitation was carried out di-
rectly using the sheared genomic DNA without any end-repair and adapter-
ligation steps. qPCR was done from immunoprecipitated and input DNA for
the glucocorticoid receptor-binding site and control region in the Hdac1
gene based on the wild-type MeDIP-sequencing data. For identification of
the GR-binding site and control region, the enriched region sequences from
the wild-type mice MeDIP-sequencing data were taken. Further analysis was
performed using the JASPER database for the identification of GR-binding
sites using the default parameters.
ChIP. All procedures were carried out in DNA low-binding tubes from
Eppendorf (or Diagenode, where indicated). Tissue was lysed in radio-
immunoprecipitation assay-SDS [140 mM NaCl, 1 mM EDTA, 1% Triton
X-100, 0.1% sodium deoxycholate, 10 mM Tris·HCl (pH 8), 1% SDS] buffer for
10 min at 4 °C in a rotating wheel in sonication tubes (Diagenode). Samples
were then sonicated for 20 min in a Bioruptor plus NGS device (Diagenode)
at the high setting and spun down every four cycles to ensure homogeneous
sonication. Chromatin was centrifuged at 18,000 × g for 5 min at 4 °C, and
the supernatant was snap-frozen as sheared chromatin. A small sample was
checked for efficient sonication in a Bioanalyzer (Agilent) and used to esti-
mate chromatin concentration in the sample after reversion of cross-linking,
which was achieved by treating samples with 0.1 μg/μL RNaseA (Qiagen) and
then digesting protein with proteinase K (PK; Roth). Chromatin was pre-
cleared by diluting it to 10-fold the initial volume in immunoprecipitation
buffer [150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 50 mM
Tris·HCl (pH 8), 20 mM EDTA, 0.1% SDS], adding 20 μL of protein A-coded
magnetic Dynabeads (Life Technologies), and incubating the mixture at 4 °C
for at least 4 h in a rotating wheel. For HDAC1 ChIP, 4 μL of antibody
(Diagenode) was incubated with 500 μg of precleared chromatin overnight
at 4 °C in a rotating wheel. Immunoprecipitated chromatin was then re-
covered by adding 15 μL of magnetic Dynabeds, with further incubation for
2 h at 4 °C in a rotating wheel. Samples were then washed twice with im-
munoprecipitation buffer, three times with wash buffer [100 mM Tris·HCl
(pH 8), 500 mM LiCl, 1% Nonidet P-40, 1% sodium deoxycholate, 20 mM
EDTA], twice with immunoprecipitation buffer, and twice with TE buffer
(10 mM Tris·HCl, 1 mM EDTA). Samples were kept on ice at all times. Beads
were collected with a magnetic stand (Invitrogen). After the last wash,
immunoprecipitation and input samples (input samples constituted 10% of
the material used for ChIP) were collected and eluted in 20 μL of EB buffer
[10 mM Tris·HCl (pH 8)] containing 0.1 μg/μL RNaseA and then incubated at
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37 °C for 30 min under gentle agitation in a Thermomix (Eppendorf). Sam-
ples were then further diluted 1:2 with WB buffer [100 mM Tris·HCl (pH 8),
20 mM EDTA, 2% SDS], and 1 μL of PK (20 mg/mL) was added. Samples were
then incubated overnight at 65 °C under agitation in a Thermomix. DNA was
recovered on the magnetic stand and reeluted with EB buffer for 10 min at
65 °C. Inputs were carried out in parallel after the immunoprecipitation.
DNA was precipitated with SureClean (Bioline) and linear polyacrylamide
(Ambion), washed twice with 70% EtOH, and quantified using a Qubit
Fluorometer (Life Technologies).
All buffers were supplemented with a proteinase inhibitor mixture (ref-
erence no. 04 693 132 001; Roche).
Immunoblotting and Immunohistochemistry. Brain tissue was homogenized in
TX buffer (50 mM Tris, 150 mM NaCl, 2 M EDTA, 1% Triton-X, protease in-
hibitors), incubated for 15 min at 4 °C, and centrifuged for 10 min (9,391 ×
g). The supernatant was used for immunoblotting. Immunoblots were per-
formed using fluorescent secondary antibodies, and data were quantified
using an Odyssey Imager (Licor). Antibodies were diluted either in 0.5% milk
phosphate buffered saline or 0.5% milk TRIS buffered saline, respectively.
Immunostaining was performed as described previously (14, 61) and ana-
lyzed using a Leica SP2 confocal microscope. The following antibodies were
commercially purchased and used at the cited concentrations: GAPDH
(1:5,000; Chemicon), HDAC1 (1:1,000; Diagenode), GFP, Cy3-labeled (goat
anti-rabbit, 1:500; Jackson ImmunoResearch), and Alexa 488-labeled (donkey
anti-mouse, 1:500; Invitrogen). Immunostaining was performed as described
previously (57, 62) and analyzed using a Leica SP2 confocal microscope. The
following antibodies were commercially purchased and used at the cited
concentrations: HDAC1 (1:1,000, H-51; Santa Cruz Biotechnology) and Pvalb
(1:1,000; Swant). Secondary antibodies were as follows: Alexa 633-labeled
(1:2,000, goat anti-rabbit; Jackson ImmunoResearch), Cy3-labeled (1:500, goat
anti-rabbit; Jackson ImmunoResearch), and Alexa 488-labeled (1:500, donkey
anti-mouse; Invitrogen).
Electrophysiology. Mice overexpressing HDAC1-GFP or GFP in the mPFC were
killed by cervical dislocation. After quick decapitation and removal of the brain,
400-μm-thick coronal slices containing the prefrontal area (1.9–1.1 mm anterior
to bregma) were cut using a VT1200M vibratome (Leica) in ice-cold artificial
cerebrospinal fluid (ACSF) equilibrated with 95% O2/5% CO2 and containing
the following: 250 mM sucrose, 24 mM NaHCO3, 25 mM glucose, 2.5 mM KCl,
1.25 mM NaH2PO4, 2 mM CaCl2, and 1.5 mM MgCl2 (pH 7.4). The slices were
then kept for at least 2 h before the start of recordings in ACSF that was
continuously gassed with 95%O2/5% CO2 and contained 120 mMNaCl instead
of sucrose (63). Experiments were performed in the same solution at a flow
rate of 4 mL·min−1 in a submerged chamber (2 mL) and at room temperature
(22–24 °C). Recordings of fEPSPs were performed with glass pipettes filled with
ACSF in the mPFC, including prelimbic and cingulate cortex. A stimulation
electrode (0.3–0.5 MΩ) was placed in layers II–III of the prefrontal cortex to
stimulate electrically the input fibers of pyramidal cells. Evoked fEPSPs were
recorded with a glass electrode (2–2.5 MΩ) in layer V, which is the location of
the dendrites and cell bodies of pyramidal neurons (64). Brain slices were
viewed using an Olympus microscope fitted with fluorescence and infrared
differential interference contrast videomicroscopy. Fluorescent mPFC neurons
were identified by epifluorescence, and only slices with obvious GFP ex-
pression in the prefrontal area were selected for experiments.
Basal synaptic transmission and paired-pulse facilitation (PPF) were measured
before inducing LTP. Stimulus–response curves at stimulus intensities of 40–85 μA
were constructed to measure levels of excitatory synaptic transmission. To study
short-term plasticity, PPF was assessed by recording the synaptic response to a
pair of stimuli at 0.033 Hz with an interpulse interval of 50 ms. For PPF experi-
ments, the stimulation intensity was set to elicit fEPSPs with a magnitude of
∼30% of the maximum (defined as a response with a detectable population
spike). PPF was estimated as the ratio between the slopes of the second and first
fEPSPs (percentage). Basal synaptic transmission was monitored at 0.05 Hz for a
minimum of 10 min. To induce LTP in the mPFC, five trains of TBS with an inter–
theta-train interval of 20 s were applied (65). Each train consisted of eight bursts
delivered at 5 Hz. Each burst consisted of four pulses delivered at 100 Hz. The
duration of pulses was 0.2 ms, and the stimulation intensity was set to provide
fEPSPs with amplitude of ∼50% from the value corresponding to a sweep for
which a population spike is first detectable. In all LTP experiments, the level of
LTP represents the average fEPSP slope measured during 50–60 min after TBS
normalized to the baseline fEPSP slope. The level of STP was determined as the
maximal potentiation within the first 1 min after TBS. The data were acquired
using an EPC10 amplifier at a sampling rate of 10 kHz, low-pass-filtered at 3 kHz,
analyzed using PatchMaster software (Heka Elektronik), and presented using
SigmaPlot (Systat Software, Inc.). Stimulus artifacts on figures were blanked to
facilitate the perception of fEPSPs.
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